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Proteolytic cleavage of the Her-2/neu extracellular domain (ECD) has been shown to initiate receptor phosphorylation representing
Her-2/neu activation in vitro. The present investigation was performed to evaluate the clinical relevance of ECD cleavage for Her-2/
neu activation and the consequences of active intracellular Her-2/neu signalling reflected by tyrosine kinase phosphorylation in
patients treated with the anti-Her-2/neu antibody trastuzumab. Sera from 62 patients receiving trastuzumab-based treatment for
Her-2/neu overexpressing metastatic breast cancer were assessed for pretreatment ECD levels using an enzyme-linked
immunosorbent assay. In parallel, Her-2/neu activation status of tumour specimens was assessed by immunohistochemistry using a
Her-2/neu phosphorylation state specific antibody (PN2A) and correlated with the patients’ ECD levels and clinical course of disease.
Serum ECD levels were significantly higher in 15 (24%) patients with tumours exhibiting activated Her-2/neu as compared to those
without detectable Her-2/neu phosphorylation (median 148.2 vs 28.5ngml
 1, P¼0.010). Whereas response rate only showed a
trend to be higher in patients with Her-2/neu-phosphorylated breast cancer (47 vs 34%, P¼0.197), both uni- and multivariate
analyses revealed that the median progression-free survival under trastuzumab-based treatment was significantly longer in patients
with Her-2/neu-phosphorylated breast cancer–11.7 (95% CI 5.2–18.3) months–when compared to the progression-free survival of
4.5 (95% CI 3.4–5.6) months observed in patients with tumours lacking phosphorylated Her-2/neu (P¼0.001). Proteolytic cleavage
of the ECD represents a biologically relevant ligand-independent mechanism of Her-2/neu activation in vivo. The influence of Her-2/
neu activation status upon the outcome of trastuzumab-based therapies merits further investigation in larger prospective trials.
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The human epidermal growth factor (Her-2/neu) is a 185kDa
oncoprotein (p185), which is overexpressed in 25–30% of invasive
breast cancers (Schechter et al, 1984; Slamon et al, 1987; Olayioye
et al, 2000). Her-2/neu overexpression has consistently been found
to confer resistance to cytotoxic and endocrine therapy and to
account for an aggressive biological behaviour, thereby resulting in
shorter disease-free and overall survival in both, patients with
early and advanced breast cancer (Slamon et al, 1987).
The Her-2/neu molecule is composed of an extracellular ligand-
binding domain, an amphipathic transmembrane region and an
intracellular tyrosine kinase domain, which contains a carboxy tail
with five major autophosphorylation sites (Ullrich and Schles-
singer, 1990). Ligand binding is thought to initiate the formation of
homo- and heterodimeric receptor complexes with other growth
factor receptor (GFR) class 1 family members such as EGFR, Her-3
and Her-4 into which Her-2/neu is recruited as a preferential
dimerisation partner (Tzahar et al, 1996). This process is followed
by intrinsic tyrosine kinase-mediated autophosphorylation and
mutual phosphorylation of the respective dimerisation partners
and ultimately results in activated receptor complexes (Segatto
et al, 1990; Tzahar et al, 1996). Alternatively, in vitro Her-2/neu
activation has also been demonstrated to occur as a consequence
of spontaneous cleavage of its extracellular domain (ECD) thereby
resulting in the production of a truncated membrane-bound
fragment (p95) with kinase activity (Christianson et al, 1998;
Molina et al, 2001). Since the p95 fragment has also been detected
in breast cancer specimens, it has been suggested that shedding of
the ECD may represent an alternative activation mechanism of
Her-2/neu in vivo (Christianson et al, 1998).
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lIntracytoplasmatic phosphorylated tyrosine residues of the Her-
2/neu molecule function as high-affinity binding sites for SH2
domain containing proteins, which link the receptor to intracel-
lular signal transduction processes such as the ras-raf-mitogen
activated protein kinase (MAPK) and the phosphatidylinositol-3
kinase (PI-3K) pathways. Both are believed to be key elements in
the regulation of cell proliferation and survival (reviewed in
Slichenmyer and Fry, 2001). In this context, phosphorylation of the
1248 tyrosine residue (Tyr1248), which is supposed to constitute
the main autophosphorylation site of Her-2/neu, is a key event for
downstream signalling (Akiyama et al, 1991; Dougall et al, 1994;
DiGiovanna and Stern, 1995; Marshall, 1995).
Monoclonal antibodies targeting the Her-2/neu ectodomain,
such as trastuzumab and its murine precursor 4D5, have been
shown to abrogate the Her-2/neu activation processes and to
interfere with Her-2/neu-dependent gene expression, to modulate
cell cycle progression, induce cellular differentiation and to
sensitise Her-2/neu overexpressing cells to apoptotic stimuli.
These effects are mediated by several distinct mechanisms
including the blockade of ligand binding, disruption of homo-
and heterodimer formation, induction of receptor internalisation
and degradation as well as prevention of cleavage of the ECD
(Baselga et al, 2001; Yip and Ward, 2002), all of which ultimately
result in a decrease of receptor phosphorylation in vitro (Kumar
et al, 1991; Lane et al, 2000). An intact tyrosine kinase activity
appears to be the main precondition for growth inhibition induced
by trastuzumab, since the regular functions of all of the mentioned
mechanisms depend upon Her-2/neu kinase integrity (Xu et al,
1994).
These observations have been successfully translated into
clinical use. Thus, trastuzumab has not only demonstrated activity
as a single agent, but had also exerted synergistic activity when
administered in conjunction with cytotoxic drugs, thus resulting in
prolonged progression-free and overall survival in patients with
Her-2/neu overexpressing metastatic breast cancer (Slamon et al,
2001; Vogel et al, 2002). Currently, the decision for treating
patients with metastatic breast cancer with trastuzumab is based
upon the detection of Her-2/neu overexpression and/or amplifica-
tion of the c-erbB-2 gene determined by immunohistochemistry
(IHC) and fluorescence in situ hybridisation (FISH), respectively.
However, aside from the intensity of Her-2/neu overexpression,
additional factors that would predict the effectivity of trastuzumab
as single agent or in combination with cytotoxic treatment are still
lacking. Since tyrosine kinase activation is the downstream
mechanism of action for Her-2/neu, it has been postulated that
tumours exhibiting active Her-2/neu signalling represented by
phosphorylation of tyrosine residues might be those most sensitive
to treatment with trastuzumab (DiGiovanna and Stern, 1995; Thor
et al, 2000).
The aim of the present study was to determine whether cleavage
of the Her-2/neu ECD is correlated with overall tyrosine kinase
activity in vivo and might therefore constitute a clinically relevant
ligand-independent mechanism for the activation of Her-2/neu in
breast cancer. In addition, we correlated the clinical course of
disease of patients treated with trastuzumab with Her-2/neu
phosphorylation status to determine the clinical relevance of active
Her-2/neu signalling.
MATERIALS AND METHODS
Patient population–inclusion and exclusion criteria
Patients who had received trastuzumab (Herceptin
s, Roche
Pharmaceuticals, Vienna, Austria)7chemotherapy at our institu-
tion between April 2000 and February 2003 in accordance with
previously published treatment protocols (Pegram et al, 1998;
Cobleigh et al, 1999; Burstein et al, 2001; Miller et al, 2001;
Seidman et al, 2001; Slamon et al, 2001; Esteva et al, 2002; Vogel
et al, 2002) were identified retrospectively by using pharmacy
protocols. Trastuzumab was administered as 4mgkg
 1 loading
dose followed by a weekly 2mgkg
 1 maintainance dose, as
described in Cobleigh et al (1999), to patients with metastatic
breast cancer with grade 2þ or 3þ Her-2/neu overexpression
assessed by immunohistochemistry. Patients included into the
present analysis were required to have bidimensionally measurable
(with both diameters 41.0cm and at least one lesion with both
diameters 41.5cm) disease (excluding previously irradiated or
bone lesions as the only site of measurable disease) with clearly
defined margins and radiologically (CT and/or MRI and/or
ultrasound) documented tumour progression before initiation of
trastuzumab-based treatment.
In addition, patients’ records were required to contain
documented response assessment performed every 6–8 weeks
(depending on the therapeutic regimen). Response evaluation was
performed by independent review of patients records and
radiology reports by two investigators and classified in accordance
with the Southwest Oncology Group response criteria and end
point definitions (Green and Weiss, 1992). Patients who had
discontinued treatment before radiological response assessment or
had been lost to follow-up (as defined by the last record obtained
48 weeks before the present analysis) were censored as
therapeutic failures or deaths, respectively. Patients who had
previously received treatment with monoclonal antibodies, vac-
cines or biological response modifiers were excluded. Further
inclusion criteria consisted of availability of intact paraffin-
embedded tissue (excluding mechanically altered tissue and fine
needle aspirates) from which the original assessment of Her-2/neu
overexpression had been performed and deep-frozen ( 801C) sera
that had been obtained immediately before the first infusion of
trastuzumab. In accordance with our institutional ethical commit-
tee guidelines, signed informed consent was obtained from all
patients before 8ml of blood was drawn from the same venous
access, which was afterwards immediately used for infusion of
trastuzumab. Data on oestrogen and progesterone receptor status
of tissue samples from which the original assessment of Her-2/neu
overexpression had been performed were available from pathology
records.
Determination of Her-2/neu overexpression
In all cases, reassessment of Her-2/neu overexpression and
determination of Her-2/neu phosphorylation were performed
independently by two experienced pathologists blinded to the
clinical course of patients and the results of other tests performed.
All testing was performed in the identical tissue material used for
initial patient selection for trastuzumab therapy. Her-2/neu
protein expression was evaluated on paraffin-embedded tissue
using the HercepTest kit (DAKO A/S, Glostrup, Denmark) for
immunoenzymatic staining in accordance with the protocol
described in the manufacturer’s guide: tissue sections were
dewaxed in xylene and then rehydrated through ethanol to
distilled water. Subsequently, tissue sections were immersed in
epitope retrieval solution (DAKO) at 951C, and then in waterbath
at 951C for a total of 40min, followed by a 20min cool-down
period at room temperature. Slides were incubated at room
temperature with the primary rabbit polyclonal antibody to the
Her-2/neu oncoprotein (supplied by the kit manufacturer) on a
DAKO Autostainer for 30min followed by application of
peroxidase-blocking reagent. Antibody was localised by incubating
slides with the DAKO Visualization Reagent using horseradish
peroxidase-conjugated goat anti-rabbit immunoglobulins for
30min using the DAKO Autostainer. Sections were finally
incubated with diaminobenzidine (DAB) as chromogen and
counterstained with haematoxylin. To assess the expression of
the Her-2/neu oncoprotein accurately, positive controls consisting
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and a control slide consisting of three pelleted, formalin-fixed,
paraffin-embedded human breast cell lines with staining intensity
scores of 0, 1þ and 3þ (supplied by the kit manufacturer) were
included in each staining run. Negative controls were performed
by substitution of the HER-2/neu primary antibody by normal
rabbit serum (DAKO Negative Control Reagent). Only membrane
staining intensity and pattern were evaluated using the 0 to 3þ
scale as illustrated in the HercepTest kit scoring guidelines.
Determination of Her-2/neu gene amplification
In cases of 2þ immunostaining for Her-2/neu, oncoprotein gene
copy number of the HER-2/neu (c-erbB-2) gene was determined by
dual-colour FISH referring to the numbering of chromosome 17
using the PathVysion
s HER-2 DNA probe-kit (Vysis Inc.,
Downers Grove, IL, USA) according to the manufacturer’s
directions. The HER2/neu-SpectrumOrange probe contains a
DNA sequence specific for the c-erbB-2 human gene locus and
hybridises to region 17q11.2–q12 of human chromosome 17. The
CEP 17 (chromosome enumeration probe 17)/SpectrumGreen
probe contains alpha-satellite DNA that hybridises to the D17Z1
locus (centromere region of chromosome 17). Fluorescence was
evaluated by using a Nikon E600 microscope with a Y-Fl Epi-
Fluorescence Attachment (Nikon, Tokyo, Japan) and a black-and-
white, charge-coupled device (CCD) camera (COHU 4912; Cohu,
San Diego, CA, USA) run by Lucia-Fish software (Laboratory-
Imaging, Prague, Czech Republic). Fluorescence in situ hybridisa-
tion slides were compared with adjacent haematoxylin/eosin slides.
Her-2/neu signals and CEP17 signals in at least 20 cancer nuclei
per tumour were scored. A cell was considered amplification
positive if the Her2/neu:CEP17 ratio exceeded 2.
Determination of specifity of phospho-specific (P-Tyr1248)
Her-2/neu antibody (PN2A)
Her-2/neu (p185) overexpressing SKBR3 human mammary
carcinoma cells (American Type Culture Collection, Rockville,
MD, USA) were cultured in McCoy’s 5A modified medium (Gibco
BRL, Paisley, Scotland), supplemented with 15% of heat-inacti-
vated fetal calf serum (FCS), glutamine and 50IU penicillin and
50mgml
 1 streptomycin (all Gibco) in a humidified atmosphere
containing 5% CO2. Confluent SKBR3 cells were cultivated in six-
well plates (Corning Inc., NY, USA) and serum starved in medium
containing 0.1% FCS overnight. Since epidermal growth factor
(EGF) has been shown to stimulate tyrosine phosphorylation of
Her-2/neu dramatically (DiGiovanna and Stern, 1995), cells were
then incubated with and without EGF (human rEGF, Strathmann
Biotech AG, Hamburg, Germany) at 100ngml
 1 for 2, 4, 8, 10, 30
and 60min at room temperature. To maximise differential
phosphorylation of p185 isolated from EGF-treated cells, the
phosphotyrosine phosphatase inhibitor sodium ortho-vanadate
(Alexis Biochemicals, QBIOGENE Inc., Carlsbad, CA, USA) was
added at a final concentration of 500mM during the final hour prior
to stimulation of cultures that were to be stimulated with EGF.
After incubation, cells were lysed in 0.5ml1 Laemli buffer and
boiled at 961C for 10min.
To perform Western blotting, cell lysates were separated on a
7.5% SDS–polyacrylamide electrophoretic gel (PAGE) with a
constant voltage of 200V for 30min and transferred to a
nitrocellulose membrane (Novex) by electroblotting (20V, 1h).
SeeBlue
s Pre-stained Standards (250, 98 and 64kDa) (Novex,
Invitrogen, Paislay, UK) were used as molecular weight standards.
Membranes were incubated in blocking solution for 1h at room
temperature and treated afterwards with 1mgml
 1 of mouse
monoclonal antibody: (A) mouse monoclonal c-erbB-2/HER-2/neu
Ab-20 (L87þ2ERB19), (B) c-erbB-2/HER-2/neu (phospho-speci-
fic) Ab-18 (clone PN2A, both NeoMarkers, Fremont, CA, USA) at
room temperature for 2h. Membranes were incubated in alkaline
phosphatase-coupled anti-mouse antibody for 1h at room
temperature after a 30min wash. Following another washing, the
membranes were incubated in 4-nitro blue tetrazolium chloride/5-
bromo-4-chloro-3-indolyl phosphate (NBT/BCIP, Roche Diagnos-
tics GmbH, Vienna, Austria) developer solution for 10min.
Membranes were developed and finally washed with bidistilled
water.
Determination of Tyr1248 Her-2/neu phosphorylation of
tumour samples
Determination of Her-2/neu phosphorylation was performed using
the monoclonal antibody PN2A (NeoMarkers, Westinghouse
Drive, Fremont, CA, USA). As demonstrated by Western blotting
analysis (see above and Green and Weiss, 1992) and immunohis-
tochemistry using peptide blocking experiments (Green and
Weiss, 1992) the PN2A antibody specifically recognises phosphor-
ylation of the major autophosphorylation site Tyr-1248 (P-
Tyr1248) without crossreactivity with c-erbB-1 (EGFR), c-erbB-3
or c-erbB-4, or unphosphorylated Her-2/neu. Formalin-fixed
paraffin-embedded tissue sections (4mm) were deparaffinised,
rehydrated, and endogenous peroxidase-blocked with 2% hydro-
gen peroxide. Antigen retrieval was performed by placing sections
in 10mmoll
 1 citrate buffer (pH 6.0) and microwave treatment for
15min. Slides were allowed to cool to room temperature (RT),
washed with phosphate-buffered saline (PBS) and distilled water,
and blocked with Ultra V Block (Lab Vision, Westinghouse Drive,
Fremont, CA, USA). PN2A (6mgml
 1) was applied and sections
were incubated at 41C overnight. After two additional PBS washes,
sections were sequentially incubated at RT for 30min with
biotinylated goat anti-polyvalent (Lab Vision, Westinghouse
Drive, Fremont, CA, USA) and streptavidin-HRP (Lab Vision,
Westinghouse Drive, Fremont, CA, USA). Subsequently, slides
were incubated with 3-amino-9-ethylcarbazole (AEC, a widely
used chromogen), counterstained with haematoxylin and cover-
slipped.
Expression of phosphorylated Her-2/neu was visually assessed
using the same scoring system applied for determination of Her-2/
neu overexpression (see above). In contrast to evaluation of
receptor overexpression of Her-2/neu (considering grade 2þ and
grade 3þtumours positive), tumours exhibiting a clearly dis-
cernible positive signal for receptor phosphorylation (Xgrade
1þusing Herceptest guidelines) on cellular membranes were
considered positive, because even weak staining for phosphoryla-
tion of the 1248 tyrosine residue of the Her-2/neu molecule
(pHER-2/neu) might represent tyrosine kinase activity, that is,
active receptor signalling. In contrast, faint cytoplasmatic staining
in the absence of membraneous staining was not considered
positive. For each assay, pelleted, formalin-fixed, paraffin-
embedded human T47D and rhEGF-stimulated SKBR-3 breast
cancer cell lines (American Type Culture Collection, Rockville,
MD, USA) were used as positive controls. Photomicrographs of
immunohistochemical analysis for Her-2/neu overexpression and
Her-2/neu phosphorylation are depicted in Figure 1.
Determination of serum Her-2/neu ECD levels
Sera obtained immediately before the first infusion of trastuzumab
were analysed using a Sequential Solid Phase Sandwich Human
Her-2/neu Quantitative ELISA (Her-2/neu Microtiter ELISA,
Oncogene Science, Cambridge, MA, USA) according to the
manufacturer’s instructions. Microplates were washed using an
automated washer (Dias Microplate Washer, Dynex Technologies,
Denkendorf, Germany). Absorbance reading was performed using
an automated reader (FLUOstar Galaxy, BMG Labtechnologies,
Offenburg, Germany) and serum ECD concentrations were
calculated from absorbance data using the Fluoscan Galaxy
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lsoftware (vers. 4.20-0, BMG Labtechnologies, Offenburg, Germany).
Intra- and interassay precision of the assay were always o5% CV.
Statistical analysis
Frequencies of patients’ characteristics were compared by Fisher’s
exact test, and differences in Her-2/neu ECD levels, age and
recurrence-free interval (time from initial diagnosis to appearance
of metastatic disease) with Mann–Whitney’s U-test. After
performance of a normalising transformation on serum Her-2/
neu ECD, a multiple analysis of variance (ANOVA) was assessed
using serum Her-2/neu ECD as dependent variable. Relationships
between serum Her-2/neu ECD and the presence of phosphoryla-
tion were adjusted by the grade of Her-2/neu overexpression, the
presence or absence of visceral metastases and the number of sites
with metastatic disease. The results of the multiple analysis of
variance are represented by medians and 95% confidence intervals
(95% CI). For all subsequent analyses, grade of Her-2/neu
overexpression (2þ vs 3þ), presence or absence of Tyr1248
phosphorylation, patient age, recurrence-free interval, anthracy-
cline pretreatment (for early breast cancer or metastatic disease),
number of prior chemotherapeutic regimens for metastatic
disease, oestrogen receptor (ER) and progesterone receptor
(PgR) status, Karnofsky’s performance index, presence or absence
of visceral metastases (liver and/or lung), number of organs
involved by metastatic disease, type of treatment (single-agent
trastuzumab vs combination with chemotherapy) and baseline
serum Her-2/neu ECD levels were entered as variates. Multiple
logistic regression analyses were used to determine whether any of
these variates could predict response or clinical benefit (response
or disease stabilisation) from trastuzumab-based treatment. In
analogy, multiple Cox regression models were utilised to identify
the properties of the predictors mentioned above on progression-
free and overall survival. Confounders without significant influ-
ences were removed by the backward selection method based on
the Wald statistic. The related risk (RR), the odds ratio (OR), and
95% CI were calculated with the proportional hazard method in
respect of Cox regression and logistic regression. Survival curves
(progression-free and overall survival) were compared with the
log-rank test. For all analyses, a P-value o5% was considered
statistically significant. SPSS statistical software system (SPSS Inc.,
Chicago, IL, USA, version 10.0) was used for all calculations.
RESULTS
Study population
A total of 69 patients with Her-2/neu overexpressing metastatic
breast cancer, who received trastuzumab-based treatment at our
institution during the indicated period, were identified. Seven
patients were excluded for the present analysis due to the following
reasons: nonavailability of tissue samples from which determina-
tion of Her-2/neu overexpression had been performed (one
patient), mechanically altered tissue samples not amenable for
subsequent testing (one patient), nonavailability of sera obtained
immediately before the first infusion of trastuzumab (five
patients). Thus, the final study population comprised 62 patients
(median age 52.6, range 27.6–80.9 years). Patients’ characteristics
are depicted in accordance to Her-2/neu phoshorylation status
(pHER-2/neu) of tumour samples in Table 1. This analysis covers a
median observation period of 22.4 (range 6.1–37.8) months,
during which 19 (31%) objective responses (including eight
complete responses) were observed, 19 (31%) patients experienced
durable disease stabilisation (X4 months) and 24 (39%) of
patients had primarily progressive disease. As of February 2003,
55 (89%) patients had experienced disease progression and 28
(45%) deaths had occurred, all of which were attributed to disease
progression. No patient was lost to follow-up. Median (95% CI)
progression-free and overall survival calculated from survival
function were 5.7 (95% CI 2.5–8.9) and 23.8 (95% CI 16.7–30.8)
months, respectively.
Specifity of phospho-specific (P-Tyr1248) Her-2/neu
antibody (PN2A)
Figure 2 shows the results of Western blotting performed on EGF-
stimulated SKBR3 cells by using the PN2A (Figure 2B) and the
control Her-2/neu antibody (Figure 2A). Whereas the Her-2/neu
Figure 1 Immunohistochemical analysis of two (grade 3þ) Her-2/neu overexpressing tumours (upper row) differing with respect to Her-2/neu
phosphorylation status at the tyr1248 residue (lower row): strong (left) and absent Her-2/neu phosphorylation (right).
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lTable 1 Patients and treatment characteristics according to phosphorylation status of Her-2/neu (pHer-2/neu)
pHer-2/neu positive
(n¼15)
pHer-2/neu negative
(n¼47) P-value
Median age (range) (years) 52.9 (27.6–73.5) 52.2 (23.4–80.9) 0.616
a
Her-2/neu expression Grade 2+ 3 (20%) 5 (11%)
Grade 3+ 12 (80%) 42 (89%) 0.388
b
Oestrogen receptor status Positive 3 (20%) 17 (36%)
Negative 12 (80%) 30 (64%) 0.346
a
Progesterone receptor status Positive 3 (20%) 9 (19%)
Negative 12 (80%) 38 (81%) 1.000
b
Histologic type Ductal 12 (80%) 40 (85%)
Other 3 (20%) 7 (15%) 0.693
b
Grading 1 1 (7%) 1 (2%)
2 1 (7%) 9 (19%)
3 13 (87%) 37 (79%) 0.384
c
Sites of active disease Breast 2 (13%) 8 (17%) 0.545
a
Axilla 1 (7%) 7 (15%) 0.667
a
Liver 10 (67%) 25 (53%) 0.390
a
Lung 5 (33%) 22 (47%) 0.390
a
Skin/soft tissue 1 (7%) 10 (21%) 0.268
a
Distant lymph nodes 5 (33%) 24 (51%) 0.254
a
Bone 9 (60%) 23 (49%) 0.558
a
Other 3 (20%) 17 (36%) 0.346
a
Number of organs affected by metastatic disease 1 or 2 9 (60%) 24 (51%)
More 6 (40%) 23 (49%) 0.570
a
Metastatic disease to visceral organs 13 (87%) 35 (74%) 0.484
a
Median (range) recurrence-free interval (months) 20.7 (0.0–85.4) 23.0 (0.0–108.6) 0.755
a
Anthracycline pretreatment (for primary and/or metastatic
breast cancer)
Yes 14 (93%) 41 (87%)
No 1 (7%) 6 (13%) 1.000
b
Number of previous chemotherapeutic regimens for
metastatic disease
0 11 (73%) 33 (70%)
1 1 (7%) 10 (21%)
2 or more 3 (20%) 4 (9%) 0.188
c
Karnofsky’s performance status X70% 8 (53%) 26 (55%)
o 70% 7 (47%) 21 (45%) 1.000
b
Treatment Single-agent trastuzumab
(Cobleigh et al, 1999) 1 (7%) 5 (11%)
Trastuzumab+vinorelbine
(Burstein et al, 2001) 11 (73%) 24 (51%)
Trastuzumab+docetaxel
(Esteva et al, 2002) 1 (7%) 8 (17%)
Trastuzumab+paclitaxel
(Seidman et al, 2001) 1 (7%) 4 (9%)
Trastuzumab+other
chemotherapeutic agents
(Pegram et al, 1998; Miller
et al, 2001)
1 (7%) 6 (13%) 0.654
b
aMann–Whitney U-test.
bFisher’s exact test (two-sided).
cPearson’s w
2.
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Figure 2 Western blot analysis demonstrating the phosphorylation state specifity of the PN2A antibody. Specifity of (A) anti-Her-2/neu (p185) antibody
and (B) anti-phospho (tyr1248) Her-2/neu antibody (PN2A) is shown by Western blot analysis of whole-cell lysates. SKBR3 cells were treated without
(lanes A1 and B8) and with 100ngml
 1 EGF for 2 (lanes A3 and B6), 4 (lanes A4 and B5), 8 (lanes A5 and B4), 10 (lanes A6 and B3), 30 (lanes A7 and B2)
and 60 (lanes A8 and B1)min (kDa, molecular weight in kilodalton, molecular weight markers at 250, 98 and 64kDa).
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lantibody detects Her-2/neu independent of its activation status,
the PN2A antibody specifically recognises the activated, tyrosine
phosphorylated (P-Tyr1248) form of Her-2/neu. This is supported
by enhanced tyrosine kinase activities (larger PN2A bands from
left to right until point of saturation) corresponding to different
treatment periods of SKBR3 cells with EGF (compare Figure 2B,
lanes 8, 6-3).
Frequencies of Her-2/neu gene amplification, protein
overexpression and receptor activation
Immunohistochemical analysis for Her-2/neu expression demon-
strated grade 2þ overexpression in eight (13%) and grade 3þ
staining in 54 (87%) of tumour samples. FISH analysis of grade
2þ Her-2/neu overexpressing samples did not reveal gene
amplification in any of the specimens examined. Positive
immunohistochemical staining of the cell membranes for phos-
phorylation of the Her-2/neu 1248 tyrosine residue (tyr1248) was
observed in 15 (24%) tissue samples with intense staining detected
in four, moderate staining in three and weak, but clearly
discernible staining for receptor phosphorylation in eight tissue
samples, respectively. Moderate or intense staining for tyr1248
(pHer-2/neu) was associated with grade 3þ Her-2/neu over-
expression in all cases, whereas weak staining for tyr1248 was
observed in five grade 3þ and three grade 2þ Her-2/neu
overexpressing tumours.
Correlation of serum Her-2/neu ECD levels with pHER-2/
neu status
Patients with Her-2/neu phosphorylation presented with signifi-
cantly higher serum Her-2/neu ECD levels before initiation of
trastuzumab-based treatment (median 148.2, range 6.1–
510.0ngml
 1) as compared to patients without Her-2/neu
phosphorylation (median 28.5, range 5.2–6076.2ngml
 1; Mann–
Whitney test: P¼0.010, Figure 3).
Serum Her-2/neu ECD levels have also been reported to
correlate with the intensity of immunohistological Her-2/neu
overexpression–with lower values observed in patients with grade
2þ Her-2/neu-positive tumors–and to correlate with tumour
mass (Leitzel et al, 1992; Krainer et al, 1997; Kostler et al,
manuscript submitted). In our patient collective, serum ECD levels
(median, range) also tended to be higher in patients with grade
3þ Her-2/neu overexpressing tumours (45.2, 5.2–6076.2ngml
 1)
than in patients with grade 2þ Her-2/neu overexpressing tumours
(15.4, 11.2–245.4ngml
 1), but without statistical significance
(P¼0.734). Therefore, we also performed a correlation between
serum Her-2/neu ECD levels and pHer-2/neu expression in the
subset of grade 3þ Her-2/neu overexpressing tumours. In this
subset, pHer-2/neu expressing cancers were again found to have
higher median (range) serum ECD values of 108.4 (6.1–
510.0)ngml
 1, as compared to patients without pHer-2/neu
expression (35.9, 5.2–6076.2ngml
 1). However, this difference
was not significant (P¼0.061), presumably because of the small
sample size. Figure 3 depicts serum Her-2/neu ECD levels according
to Her-2/neu overexpression and phosphorylation status.
The association between serum Her-2/neu ECD levels and Her-
2/neu phosphorylation status was adjusted by the grade of Her-2/
neu overexpression and the presence/absence of visceral metas-
tases in a multiple analysis of variance (ANOVA) with normalised
Her-2/neu ECD as criterion variable. As shown in Table 2, patients
with Her-2/neu phosphorylation had an adjusted median serum
Her-2/neu ECD concentration of 41.2 (95% CI 17.5–97.3)ngml
 1,
which was significantly higher as compared to patients without
Her-2/neu phosphorylation having an adjusted median serum ECD
level of 18.5 (95% CI 9.3–36.7)ngml
 1 (P¼0.046). The adjusted
median serum Her-2/neu ECD concentration of patients with
visceral metastases amounted to 59.4 (95% CI 32.4–109.0)ngml
 1
in comparison to patients without visceral metastases having 12.8
(95% CI 5.0–33.1)ngml
 1 (P¼0.001). The grade of Her-2/neu
overexpression and the number of sites with metastatic disease did
not show a significant correlation with serum Her-2/neu ECD levels.
Correlation of pHer-2/neu status, histopathological and
patients’ characteristics with response to trastuzumab-
based treatment
Both objective response rates–seven out of 15 (47%) vs 12 out of
35 (34%, P¼0.197)–and rates of clinical benefit–12 out of 15
(80%) vs 26 out of 47 (55%, P¼0.129)–to trastuzumab-based
treatment tended to be higher in patients with tumours exhibiting
tyr1248-phosphorylated Her-2/neu as compared to those without
pHer-2/neu expression.
Multiple logistic regression analyses were performed to evaluate
the predictive role of Her-2/neu tyr1248 phosphorylation status
upon response and benefit from trastuzumab-based treatment. In
all analyses, grade of Her-2/neu overexpression, patient age,
recurrence-free interval, anthracycline pretreatment, number of
prior chemotherapeutic regimens for metastatic disease, ER and
PgR status, Karnofsky’s performance index, presence or absence of
visceral metastases, number of organs involved by metastatic
disease, type of treatment (single-agent trastuzumab vs combina-
tion with chemotherapy) and baseline serum Her-2/neu ECD levels
were entered as variates.
In univariate analysis, none of the variates mentioned above
significantly predicted response with significance levels below
10%. Her-2/neu phosphorylation status was the only variate
showing a trend to predict benefit (for descriptive values see
Table 3).
In multivariate analysis, no significant predictors of response to
trastuzumab-based treatment were identified; again, Her-2/neu
phosphorylation status was the only covariate that revealed a trend
to significant prediction of response to trastuzumab-based
treatment, whereas no predictors of clinical benefit were identified
in multivariate analysis (Table 3).
Correlation of pHer-2/neu status, histopathological and
patients’ characteristics with progression-free and overall
survival from trastuzumab-based treatment
In patients with tyr1248 Her-2/neu phosphorylation, the median
(95% CI) progression-free survival calculated from survival curves
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longer as compared to the median (95% CI) progression-
free survival of 4.5 (3.4–5.6) months observed in patients
without pHer-2/neu staining tumours (log-rank test: Po0.0095).
Figure 4 depicts progression-free survival curves according to
Her-2/neu phosphorylation status. Median progression-free
survival (4.4, 95% CI 2.8–6.0 months) of patients with Her-2/neu
ECD levels below 15ngml
 1 did not differ significantly f
rom progression-free survival of patients with Her-2/neu ECD
above 15ngml
 1 (6.7, 95% CI 2.3–11.2 months, log-rank test:
P¼0.129).
Univariate Cox regression analysis revealed that grade 3þ Her-
2/neu overexpression, presence of Her-2/neu phosphorylation and
low number of organs involved by metastatic disease were
significant predictors of longer progression-free survival, whereas
a good performance status showed a trend to a reduced risk of
progression (descriptive values are depicted in Table 3). Multi-
variate Cox regression analysis showed that grade 3þ Her-2/neu
overexpression, presence of visceral metastases and Her-2/neu
tyr1248 phosphorylation were independent predictors of longer
progression-free survival, whereas a higher number of organs
affected by metastatic disease represented a significant adverse
predictor of progression-free survival (Table 3).
Median (95% CI) overall survival in patients without pHer-2/neu
expression was 23.8 (18.1–29.5) months and did not differ
significantly from overall survival observed in patients with
pHer-2/neu expressing tumours, which had not been reached at
the time of these analyses (log-rank test: P¼0.6842). Likewise,
median overall survival of patients with Her-2/neu ECD levels
below 15ngml
 1 was not reached during the observation period.
Patients with Her-2/neu ECD levels above 15ngml
 1 had a median
overall survival of 19.6 (95% CI 13.2–26.6 months, log-rank test:
P¼0.143).
In univariate Cox regression analysis for overall survival grade
3þ Her-2/neu overexpression, a low number of organs affected by
metastatic disease and good performance status were significant
predictors for longer overall survival, whereas serum Her-2/neu
ECD levels observed at baseline did not cause significant effects
Table 2 Multiple analysis of variance (ANOVA) applied to Her-2/neu ECD as normalised criterion variable
Median (95% CI) serum ECD (ngml
 1) P-value
Tyr1248 Her-2/neu Unphosphorylated 18.5 (9.3–36.7)
Phosphorylated 41.2 (17.5–97.3) 0.046
Visceral metastases No 12.8 (5.0–33.1)
Yes 59.4 (32.4–109.0) 0.001
Grade of Her-2/neu
overexpression
2+ 19.0 (5.9–61.2)
3+ 40.1 (24.8–65.0) 0.211
Number of organs with
metastatic disease
1 or 2 27.5 (13.0–58.3)
More than 2 27.7 (12.8–59.9) 0.986
Table 3 Clinical and histopathological predictors of response (complete or partial), clinical benefit
(response or disease stabilisation), progression-free survival (PFS) and overall survival (OAS) with significance
levels below 10% (Po0.1) in univariate and multivariate analyses RR¼related risk; 95% CI¼95% confidence
interval
Variable RR 95% CI P-value
Response
Univariate — — — —
Multivariate Her-2/neu phosphorylation 3.08 0.85–11.20 0.088
Benefit
Univariate Her-2/neu phosphorylation 3.23 0.81–2.97 0.098
Multivariate — — — —
PFS
Univariate Grade 3+Her-2/neu overexpression 0.44 0.20–0.95 0.036
Her-2/neu phosphorylation 0.41 0.21–0.82 0.012
Higher number of metastatic sites 2.09 1.21–3.63 0.009
Good performance status 0.61 0.35–1.05 0.074
Multivariate Grade 3+Her-2/neu overexpression 0.34 0.12–0.93 0.037
Presence of visceral metastases 0.38 0.17–0.86 0.020
Her-2/neu phosphorylation 0.38 0.18–0.81 0.012
Higher number of metastatic sites 2.66 1.33–5.32 0.006
OAS
Univariate Grade 3+Her-2/neu overexpression 0.11 0.04–0.27 o0.001
Serum Her-2/neu at baseline 1.00 1.00–1.00 0.076
Higher number of metastatic sites 4.71 2.10–10.56 o0.001
Good performance status 0.28 0.13–0.60 0.001
Multivariate Higher number of metastatic sites 3.79 1.55–9.26 0.003
Grade 3+Her-2/neu overexpression 0.15 0.05–0.48 0.001
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analyses, a low number of organs affected by metastatic disease
and grade 3þ Her-2/neu overexpression yielded a reduced risk of
death within the observation period (Table 3).
DISCUSSION
The present investigation was performed to evaluate a potential
correlation of tyrosine phosphorylated Her-2/neu with cleavage of
its ECD in breast cancer patients, and to determine the clinical
consequences of Her-2/neu activation with respect to the efficacy
of trastuzumab-based treatment. We here report that, in Her-2/neu
overexpressing tumours, increased serum Her-2/neu ECD levels
are indeed associated with active Her-2/neu tyrosine kinase
signalling, as represented by Tyr1248-phosphorylated Her-2/neu.
Our findings strongly support the clinical relevance of previous in
vitro observations, which have demonstrated that spontaneous
proteolytic cleavage of the ECD represents a ligand-independent
activation mechanism of Her-2/neu (Molina et al, 2001).
In this context, it is interesting to note that the detection of
increased serum levels of the Her-2/neu ECD has been associated
with increased resistance to endocrine therapy in Her-2/neu
overexpressing metastatic breast cancer (Lipton et al, 2002),
thereby suggesting that resistance to antihormonal agents was
associated with active Her-2/neu-dependent signalling. On the
other hand, serum Her-2/neu ECD levels have been associated with
increased response rates and prolonged progression-free survival
to subsequent trastuzumab-based treatment (Esteva et al, 2002;
Kostler et al, manuscript submitted). It can, therefore, be
hypothesised that not only the mere Her-2/neu overexpression,
but also its activation status are crucial for susceptibility to the
biological effects of trastuzumab in vivo.
Based on these assumptions, we have determined the impact of
the Her-2/neu phosphorylation on the clinical outcome of patients
with Her-2/neu overexpressing metastatic breast cancer receiving
trastuzumab-based treatment. In the present analysis, we have
found a trend towards higher response rates and higher rates of
clinical benefit in patients with activated Her-2/neu. Notably,
progression-free survival to trastuzumab-based treatment was
more than doubled in patients with tumours exhibiting activated
Her-2/neu as compared to patients lacking tyrosine-phosphory-
lated Her-2/neu. Whether this observation can be attributed to an
increased and prolonged sensitivity to trastuzumab-based treat-
ment or represents an intrinsic biologic characteristic of tumours
exhibiting tyr1248 phosphorylation of Her-2/neu remains to be
determined in future prospective trials evaluating the predictive
value of pHer-2/neu for various forms of treatment.
In addition, the absence of Tyr1248 phosphorylation does not
necessarily preclude Her-2/neu-dependent signalling: although
Her-2/neu activation is thought to be a hierarchical event in
which Tyr1248 is the ultimate C-terminal site to be phosphorylated
before downstream signalling occurs (Akiyama et al, 1991; Harder
et al, 1994), it is conceivable that interactions of other
phosphorylated (non)tyrosine residues with heterodimerisation
partners resulting in heterodimerisation partner-dependent sec-
ondary signalling (Graus-Porta et al, 1997; Olayioye et al, 1998,
2000; Ouyang et al, 2001) could also be targeted by trastuzumab.
The characterisation these activation states, of stimulatory and
inhibitory interactions and their correlation with the clinical
effects of trastuzumab will clearly have a profound effect on our
biologic understanding of receptor signalling and ultimately refine
targeted therapies.
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